25 LLC’s Jazz Pharmaceuticals JAZZ Stock Holding History

25 LLC’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4	Closed	-$508	–	275
2023 Q2	$508	Buy	+4	New	+$538	﹤0.01%	523

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

25 LLC's JAZZ Position: Q3 2023 in Review

25 LLC sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2023, closing a stake of 4 shares — an estimated $508 sold.

25 LLC first reported a position in JAZZ in Q2 2023 and held it in 1 quarter. The position peaked at $508 in Q2 2023. 484 funds tracked by Wall St. Rank hold JAZZ as of Q3 2023.

25 LLC reported no remaining Jazz Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
25 LLC sold 4 Jazz Pharmaceuticals shares in Q3 2023, an estimated $508.
25 LLC first reported a position in Jazz Pharmaceuticals in Q2 2023 and held it in 1 quarter.
25 LLC's Jazz Pharmaceuticals position peaked at $508 in Q2 2023.
484 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2023.

Based on 25 LLC's 13F filing for Q3 2023, filed 18 Oct 2023.